Innovent Biologics Inc - Company Profile
Powered by 
All the sales intelligence you need on Innovent Biologics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Innovent Biologics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Innovent Biologics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for therapeutic areas such as oncology, cardiovascular and metabolic diseases, autoimmune diseases, and ophthalmology. The company's oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, ramucirumab, and others. Innovent Biologics's autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company's metabolic and ophthalmology products include IBI-362, IBI-302, IBI-324, IBI-311 IGF-1R and IBI-333. It markets products under brands TYVYT, BYVASDA, SULINNO, HALPRYZA, Pemazyre, Cyramza, Retsevmo, FUCASO, and SINTBILO. Innovent Biologics is headquartered in Suzhou, Jiangsu, China
Headquarters
China
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, 215123
Website
www.innoventbio.com
Telephone
86 512 69566088
No of Employees
7,502
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1801 (HKG)
Revenue (2024)
$1.8B
38.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
959.7%
(2024 vs 2023)
Market Cap*
$17.6B
Net Profit Margin (2024)
XYZ
724.0%
(2024 vs 2023)
* As of and is in US$
Innovent Biologics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology Drugs: | TYVYT |
| Sintilimab Injection | BYVASDA |
| Bevacizumab | SULINNO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company and Pfizer entered into a collaboration to co-develop and co-commercialize early-stage oncology medicines. |
| 2026 | New Products/Services | In March, Altruist Biologics introduced Altru-CON, a high-concentration formulation technology platform. |
| 2026 | Regulatory Approval | In March, the company received NMPA approval in China for Jaypirca (pirtobrutinib) to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after prior BTK inhibitor therapy. |
Competitor Comparison
| Key Parameters | Innovent Biologics Inc | Hainan Haiyao Co Ltd | BeiGene (Beijing) Co Ltd | Beijing Tri-Prime Genetic Engineering Co Ltd | Biotech Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Suzhou | Haikou | Beijing | Daxing District | Beijing |
| State/Province | Jiangsu | Hainan | Beijing | Beijing | Beijing |
| No. of Employees | 7,502 | 1,738 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| De-Chao Michael Yu, PhD | Chairman; Chief Executive Officer | Executive Board | - | 62 |
| Vivian Zhang | Director; General Manager; Chief Financial Officer | Executive Board | 2017 | - |
| Rachel You | Chief Financial Officer | Senior Management | 2024 | - |
| Kaisong Zhou, PhD | Chief Operating Officer | Senior Management | - | - |
| Jamie Freedman, MD, PhD | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer